Search

Your search keyword '"Mueller-Tidow, Carsten"' showing total 42 results

Search Constraints

Start Over You searched for: Author "Mueller-Tidow, Carsten" Remove constraint Author: "Mueller-Tidow, Carsten" Database OAIster Remove constraint Database: OAIster
42 results on '"Mueller-Tidow, Carsten"'

Search Results

1. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

2. Phagocytosis by stroma confounds coculture studies

3. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

4. Phagocytosis by stroma confounds coculture studies

5. Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels

6. Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels

7. Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients

8. Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients

9. Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients

10. Treatment Response and Long-Term Survival in Multiple Myeloma in the GMMG-HD4 Trail - Neither Profit All Molecular Entities Alike, Nor Are Remissions to Different Regimen Equal

11. Outcome of Patients with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Beyond First Complete Remission (CR1)

12. Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse

13. Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial Relapse Suggest Survival Benefit of Salvage Autologous Transplant Primarily in Low Risk Multiple Myeloma

14. Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients

15. Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse

16. Treatment Response and Long-Term Survival in Multiple Myeloma in the GMMG-HD4 Trail - Neither Profit All Molecular Entities Alike, Nor Are Remissions to Different Regimen Equal

17. Outcome of Patients with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Beyond First Complete Remission (CR1)

18. Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial Relapse Suggest Survival Benefit of Salvage Autologous Transplant Primarily in Low Risk Multiple Myeloma

19. Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients

20. The European Hematology Association Roadmap for European Hematology Research : a consensus document

21. The European Hematology Association Roadmap for European Hematology Research : a consensus document

22. The European Hematology Association Roadmap for European Hematology Research : a consensus document

23. The European Hematology Association Roadmap for European Hematology Research : a consensus document

24. The European Hematology Association Roadmap for European Hematology Research : a consensus document

25. The European Hematology Association Roadmap for European Hematology Research: a consensus document

26. Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction

27. The European Hematology Association Roadmap for European Hematology Research : a consensus document

28. The European Hematology Association Roadmap for European Hematology Research : a consensus document

29. The European Hematology Association Roadmap for European Hematology Research: a consensus document

30. Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction

31. The European Hematology Association Roadmap for European Hematology Research : a consensus document

32. The European Hematology Association Roadmap for European Hematology Research : a consensus document

33. The European Hematology Association Roadmap for European Hematology Research : a consensus document

34. The European Hematology Association Roadmap for European Hematology Research : a consensus document

35. Allogeneic Transplantation Versus Chemotherapy as Postremission Therapy for Acute Myeloid Leukemia: A Prospective Matched Pairs Analysis

36. Allogeneic Transplantation Versus Chemotherapy as Postremission Therapy for Acute Myeloid Leukemia: A Prospective Matched Pairs Analysis

37. Allogeneic Stem Cell Transplantation Versus Conventional Postremission Therapy for Acute Myeloid Leukemia in First Complete Remission: A Matched Pairs Analysis

38. Allogeneic Stem Cell Transplantation Versus Conventional Postremission Therapy for Acute Myeloid Leukemia in First Complete Remission: A Matched Pairs Analysis

39. Sorafenib In Combination with Standard Induction and Consolidation Therapy In Elderly AML Patients: Results From a Randomized, Placebo-Controlled Phase II Trial

40. Sorafenib In Combination with Standard Induction and Consolidation Therapy In Elderly AML Patients: Results From a Randomized, Placebo-Controlled Phase II Trial

41. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

42. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

Catalog

Books, media, physical & digital resources